Business Context and Reporting Period
This Form 8-K was filed by Recursion Pharmaceuticals, Inc. on August 28, 2024. The report details a material development regarding the proposed acquisition of Exscientia plc (Exscientia) by Recursion, originally announced on August 8, 2024. The transaction is structured as a scheme of arrangement under the United Kingdom Companies Act 2006, subject to shareholder approvals and regulatory conditions.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document. Investors should refer to Recursion's most recent Form 10-K or 10-Q and Exscientia's Form 20-F for financial data.
Material Changes and Transaction Progress
The primary material change reported is the execution of an Irrevocable Undertaking by Evotec SE (Evotec), a significant shareholder of Exscientia.
- Evotec's Commitment: Evotec, holding approximately 11% of Exscientia's outstanding share capital, agreed to vote all its shares in favor of the Scheme of Arrangement and related resolutions.
- Aggregate Support: Combined with the shareholders who entered into irrevocable undertakings on August 8, 2024 (holding approximately 42%), the total support now reaches approximately 53% of Exscientia's total outstanding share capital.
- Transaction Status: The acquisition remains subject to the terms of the Transaction Agreement, including requisite stockholder approvals from both companies and the sanction of the High Court of Justice of England and Wales.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing includes forward-looking statements regarding the potential benefits of the combination, such as delivering treatments faster and at lower costs. However, the document explicitly states it is not a substitute for the upcoming joint proxy statement, which will contain full details on benefits and risks.
Risks and Contingencies: The filing outlines significant risks that could prevent the transaction's completion, including:
- Failure to obtain necessary stockholder or shareholder approvals.
- Inability to secure the sanction of the High Court of Justice of England and Wales.
- Failure to obtain required regulatory approvals.
- Disruption to ongoing business operations and diversion of management attention.
- Challenges in integrating the businesses and realizing cost synergies.
- Macroeconomic factors, including interest rate changes, inflation, and foreign currency volatility.
Investor Verification Checklist
- Verify the final terms of the Joint Proxy Statement once filed with the SEC for complete transaction details.
- Confirm the status of the High Court of Justice of England and Wales sanction for the Scheme of Arrangement.
- Monitor the voting results of Exscientia shareholders to ensure the >50% threshold is maintained and exceeded at the meeting.
- Review the Irrevocable Undertaking of Evotec SE (Exhibit 10.1) for specific conditions or exceptions to their voting commitment.
- Assess the impact of the transaction on Recursion's capital structure and potential dilution to existing shareholders.